Annual report 2014

27 Profit after taxes from discontinued operations

The profit after taxes from discontinued operations pursuant to the income statement includes the income and expenses of the Celesio division. As individual units within the Celesio division were already previously presented as discontinued operations, those units are presented separately in the following table.

Profit or loss from discontinued operations consisted of the following:

  2014 2013
EUR million Celesio
division
of which
DocMorris mail- order pharmacy,
Pharmexx and Movianto
Celesio division of which
DocMorris mail- order pharmacy,
Pharmexx and Movianto
Revenue 1,851 21,427 19
Cost of materials 1,653 19,074 16
Gross profit 198 2,353 3
Depreciation and amortisation 106
Operating profit 41 427
Result from investments accounted for at equity 4
Other investment result 1 6
Finance costs 12 145
Other net financial income -1 -4
Profit before taxes 29 288
Income tax expenses 11 97
Profit after taxes 18 0 191 0
 
Revaluation and disposal gains/losses before taxes 696 -6 -5
Income taxes on revaluation and disposal gains/losses
Revaluation and disposal gains/losses after taxes 696 0 -6 -5
 
Profit after taxes from discontinued operations according to income statement 714 0 185 -5

The discontinuation of depreciation/amortisation and the offsetting effect from the discontinuation of the equity method for the pertinent associates since the Celesio division was classified as a discontinued operation resulted in an improvement in profit after taxes by a total of EUR 9 million during the financial year (previous year: EUR 19 million).